---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123256"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:22:39.096324+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma completes Phase 3 enrollment in pulmonary sarcoidosis; topline data Q3 2025

## Summary
- Phase 3 EFZO-FIT enrolled 268 patients (target exceeded) at 85 centers in 9 countries; topline data expected Q3 2025.
- Cash, equivalents, and investments $68.9M at Sep 30, 2024; raised ~$19.4M in ATM offering post-quarter.
- R&D expenses $14.8M and G&A $3.3M in Q3 2024; cash runway projected through BLA filing for efzofitimod.
- Publication in European Respiratory Journal showed significant reduction in corticosteroid relapse with efzofitimod.
- Phase 2 EFZO-CONNECT in SSc-ILD enrolling; interim data expected Q2 2025.

## SEC filing metadata
- accession: 0000950170-24-123256
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017024123256/0000950170-24-123256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017024123256/atyr-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123256
- JSON: https://secwatch.observer/filing/0000950170-24-123256.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.